fda glp-1 compounding enforcement october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Navigating the Evolving World of
Description
Discover benefits, uses, and expert treatment options at Nu-Living.

This is the unlikely journey from desert predator to medical marvel.
GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health
This brief analyses how many Medicare beneficiaries could be eligible for the new use of Wegovy and the potential impact on Medicare spending.

It sets a new precedent for curbing appetite and burning fat

Explore the rapid growth of the GLP-1 market and how weight loss drugs are transforming industries beyond healthcare.
